← back to problem page
Whitepaper · v0.1·welfare floor·open to refutation

An optimism.fun request for startups

Infectious disease (malaria, TB, HIV)

Malaria, TB and HIV still kill millions, and the cures are cheap.

Published

2026-04-24

Authors

optimism.fun

Status

Draft · v0.1

License

CC BY 4.0

§0weekly drop · week 1

Editor’s drop

Published 2026-08-20 · optimism.fun

blackpaper · the problem

Malaria killed roughly 600,000 people in 2023, most of them children under five (WHO World Malaria Report, https://www.who.int/teams/global-malaria-programme/reports/world-malaria-report-2023). Tuberculosis kills approximately 1.3 million people a year (WHO Global TB Report). HIV/AIDS kills roughly 630,000 people a year despite antiretroviral therapy that, correctly delivered, suppresses the virus to undetectable and untransmissible levels. Add the three together and a preventable, curable, or suppressible set of infections kills on the order of 2.5 million people a year, every year, right now, in 2026. WHO's Global Burden of Disease work puts the number of humans at risk of at least one of these three infections at 2.5 billion, roughly a third of the human population. This is not a rare disease problem. It is a distribution problem at civilizational scale. The intervention economics are not in dispute. The Copenhagen Consensus, which exists specifically to rank development interventions by cost-effectiveness, places malaria bednets and TB/HIV treatment among the highest benefit-cost interventions ever measured: roughly $1 spent returns $20 to $100 in economic and welfare gains. GiveWell independently reaches the same conclusion and has directed hundreds of millions of donor dollars to exactly these interventions on that basis. This is, bluntly, the cheapest way known to prevent human death, and it has been the cheapest way known for over a decade. And the death count has stalled. WHO's own series shows malaria deaths fell from roughly 900,000 in 2004 to a low near 560,000 in 2019, then rose again to 608,000 in 2022. Progress reversed. Insecticide and drug resistance are rising in the field faster than distribution can keep pace, and funding for the interventions that work has not kept up with population growth in the highest-burden regions. This is the least intellectually contestable entry on this site. There is no debate about the science, no uncertain mechanism, no decade-away technology dependency. The bednets exist. The vaccines (RTS,S and R21) exist and are WHO-recommended. The antiretrovirals exist and cost, at negotiated Global Fund prices, under $45 a year per patient. The tuberculosis drug regimens exist. Every year this problem stays this size is a year the world had the tools and did not fully deploy them. That is the entire blackpaper: not a hard problem, a distribution failure, at a cost of 2.5 million lives a year.

whitepaper · the proposal

There is no technology to invent here. The proposal is not a new drug or a new bednet, it is closing a known, quantifiable funding and delivery gap for interventions that already work, then holding that coverage against a resistance curve that keeps moving. What would actually have to be built: procurement and last-mile delivery infrastructure at the scale of the Global Fund and Gavi, but with the coverage gaps closed rather than merely reduced; point-of-care diagnostics cheap enough (sub-dollar) to test-and-treat at the village level rather than requiring a lab visit; and, on a longer horizon, gene-drive vector control for the mosquito populations that carry malaria, which is technically closer than it was five years ago but still carries real ecological and regulatory uncertainty that has not been resolved. The tractable, buy-today layer (nets, drugs, vaccines, diagnostics) and the longer-horizon layer (gene drives, universal vaccines) should be funded and evaluated separately, because conflating them is how "someday" technology gets used to excuse not deploying "today" technology. The unlock is price, not invention. Net prices have fallen from roughly $4-5 a net a decade ago to close to $2 today (Against Malaria Foundation, https://www.againstmalaria.com/DollarsPerNet.aspx), driven by manufacturing scale and competition among suppliers. First-line HIV treatment (the TLD regimen) fell from roughly $75 a person a year in 2017 to under $45 a person a year in 2023 through Global Fund procurement agreements (Global Fund, https://www.theglobalfund.org/en/news/2023/2023-08-30-global-fund-agreements-substantially-reduce-price-first-line-hiv-treatment-below-usd45-a-year). The interventions did not get better. They got cheap enough that full coverage is now a financing decision, not a technology bet. **The market, worked from real numbers, disease by disease.** Malaria: WHO counts 2.5 billion people at risk. A treated net covering one person for one year of protection runs in the range of $1.38 to $1.90 (systematic cost-effectiveness reviews of long-lasting insecticidal nets across multiple countries), call it roughly $2/person/year all-in with distribution. 2,500,000,000 x $2/person/year = $5,000,000,000/year to give every at-risk person a funded net-year of protection. HIV: UNAIDS puts roughly 39.9 million people living with HIV worldwide. First-line generic antiretroviral therapy at Global Fund negotiated pricing runs under $45/patient/year (Global Fund, 2023 figure above). 39,900,000 x $45/patient/year = roughly $1,800,000,000/year to keep everyone currently living with HIV on suppressive treatment. Tuberculosis: WHO's Global TB Report counts roughly 10.6 million new cases a year. Per-patient treatment costs vary enormously by setting, from roughly $30 for drugs alone in the cheapest low-income delivery contexts to well over $1,000 once diagnostics and case management are included in lower-middle-income settings (systematic review of TB care costs, PMC). Using a mid-range planning estimate of roughly $500/patient for a full low-income-country treatment course: 10,600,000 x $500/patient = roughly $5,300,000,000/year. Sum the three: roughly $12 billion a year to fund full known-intervention coverage for malaria, HIV, and TB simultaneously, against the 2.5 million deaths a year the current coverage gap allows. That is the honest solving-it number, not the $200 billion/year figure this site's problem page cites for the entire global infectious-disease therapeutics and diagnostics market, which includes rich-world branded drugs, hospital care, and diseases well outside this scope. $12 billion/year is a rough, bottom-up, order-of-magnitude estimate built from real per-unit prices, not a market-sizing exercise, and it should be read as a floor: it excludes health-system strengthening, resistance monitoring, and the delivery infrastructure needed to actually reach the last mile, all of which cost more than the commodities themselves in the hardest-to-reach places. Conjecture, open to refutation: the per-unit prices are solid (cited, current), the aggregation across three diseases with very different delivery contexts is a simplification, and the real number is plausibly $15-25 billion once delivery infrastructure is priced in rather than assumed.
§1abstract

The four-axis ranking

We rank humanity’s most important problems on four quantifiable dimensions — quantity of humans affected, severity per person, current solution quality, and addressable market size — and package each as a proposal in the spirit of Musk’s Hyperloop Alpha. This document is the proposal for infectious disease (malaria, tb, hiv). Every number below is sourced and tagged with confidence. Every ranking is a conjecture, open to refutation.

Quantity · humans affected

2.5B

high

Severity · 0–1

unknown

Current solutions

4.0 / 10

med

Market size · TAM

$200.0B

med
§2problem statement

What we are trying to solve

Malaria killed ~600,000 people in 2023, mostly children under 5. Tuberculosis kills ~1.3M per year. HIV kills ~630,000 per year despite proven suppression protocols. The Copenhagen Consensus ranks these interventions among the highest benefit-cost ratios in global development, $1 of intervention returns $20-$100 in economic and welfare gains. This is the baseline anyone claiming to rank humanity's problems has to include.

§3why it persists

The gap between the world and the world that is physically possible

Today: ~1.3M deaths/yr from TB. ~600K from malaria. ~600K from HIV/AIDS. All preventable with known interventions but coverage gaps + drug resistance growing.

Current solution quality is rated 4.0 / 10 (med confidence) — meaning there is substantial unclaimed ground between what exists and what is possible. estimated — proven interventions (bednets, ARVs, DOTS) effective where deployed; coverage incomplete and resistance rising.

§4existing alternatives

Who is already working on this

5 entities are currently working on this problem across public markets, private companies, and research orgs. Each is evidence the market is real; none has obviously solved it.

Gilead Sciences

public · USA

HIV franchise leader (Biktarvy, Descovy, lenacapavir as twice-yearly PrEP). Also hep B/C, oncology.

$95.0B

GSK

public · UK

Global pharma. Manufacturer of RTS, S and R21 malaria vaccines; major HIV and TB portfolios.

$72.0B

Moderna

public · USA

mRNA platform company. Pandemic preparedness via rapid vaccine development, plus pipeline in malaria, HIV, and rare disease.

$10.5B

§5proposed direction

If we solve this, here is the world we get

After · 15 years

Malaria, TB, HIV mortality reduced 95%+ via single-dose curatives, gene-drive vector control, universal vaccines. Three of humanity’s oldest scourges effectively closed out.

Requests for startups · 3 concrete companies to build

Single-encounter curatives for TB

Tuberculosis kills 1.3M people a year and the cure requires 4–6 months of daily adherence most patients cannot sustain. Build the long-acting or single-dose regimen plus the delivery model.

why now
Long-acting injectable formulation science matured (proven in HIV PrEP); the same toolkit is unapplied to TB at scale.
shape
A drug-delivery company pairing a long-acting regimen with a field delivery and adherence model designed for high-burden, low-resource settings.
success
TB treatment becomes a single supervised encounter, and TB mortality falls like HIV mortality did after ART.

Safe, reversible gene-drive vector control

Bednets and spraying have plateaued; the mosquito is the delivery system for malaria. Build the safe, reversible, field-deployable gene-drive company for malaria vectors.

why now
Gene-drive and self-limiting designs reached field-trial readiness; the gating problems are now governance and reversibility, which are buildable.
shape
A vector-control company developing confinable/reversible drives plus the field-trial, regulatory, and community-consent apparatus to deploy them responsibly.
success
Malaria transmission collapses in deployment regions without ecological regret.

Point-of-care diagnostics under a dollar

You cannot treat what you cannot diagnose, and PCR needs a lab, cold chain, and a day. Build the paper or CRISPR diagnostic that returns an accurate result anywhere for pennies.

why now
CRISPR-based detection (SHERLOCK/DETECTR-class) moved from papers to manufacturable formats.
shape
A diagnostics company productizing instrument-free, ambient-stable tests for the high-burden infections, distributed through existing community-health rails.
success
Accurate infectious-disease diagnosis is available at the point of need anywhere on Earth for under a dollar.

full rubric + framing on the Requests for Startups page.

§6cost & scale

What the market can pay

The world is already paying $200.0B per year against this problem (global infectious-disease therapeutics + vaccines + diagnostics + delivery (WHO + IFPMA estimates); med confidence).

A successful solution does not need to capture more — it needs to redirect a meaningful slice of existing spend, plus the latent willingness-to-pay implied by the severity score above. The cost ceiling for a real solution is bounded by this number; everything cheaper is dominated, everything more expensive is a non-starter.

§7safety & considerations

What could go wrong, and how we know we are not wrong

Section in progress

Failure modes, ethical considerations, and the conditions under which this whitepaper would be falsified are being authored as the weekly cadence ships. The Deutschian commitment: every claim above is a conjecture; we publish the conditions under which we would update. Unpublished sections stay empty. A Monday newsletter is not promised. Subscribe to get the upgrade, or contribute on GitHub.

§8suggested investors

Who would back this

Capital allocators with a stated thesis or deployed portfolio in this domain. This is a starting list — Exa Websets enrichment will expand it to direct check-writers per company.

Venture Studio

Deep Science Ventures

Outcome-first venture creation. Define the holy-grail outcome, then recruit founders.

Venture Capital

Fifty Years

Every portfolio company must solve a UN SDG. Profit with purpose, no exceptions.

Venture Capital

Rise Fund (TPG)

Growth-stage impact investing with rigorous Impact Multiple of Money scoring.

§9sources & criticism invite

Where this is wrong, tell us

Every number on this page carries a source and a confidence tag. Every section open to refutation. If a citation is wrong, a number is stale, or a conjecture is unfounded — file a correction.

corrections → use the feedback widget in the nav · open issue at github.com/adamtpang/optimism.fun

Published whitepapers

One problem.Published essays, not a Monday promise.

The essays that exist are listed at /whitepapers. A new essay is not promised every Monday. Weeks with no essay are empty on purpose. Nothing here invents a back catalog.

optimism.fun uses your email address only to send low-volume project updates through Resend. You can unsubscribe with one click at any time; read the privacy policy.